Msd K.k.

Merck Sharp + Dohme Corp.

Yu Onozaki

Toshihiro Sakamoto

Yoshio Ogino

Nobuhiko Kawanishi

Yasuhiro Goto

Mark E Layton

Philip E Sanderson

Jiabing Wang

Hidetomo Furuyama

Takashi Mita

Tony Siu

Weiming Fan

Akira Naya

Michael Robert Peel

Kevin J Rodzinak

Michael A Rossi

Michael James Malaska

Bharathi Pandi

Matthew G Jenks

Hao Liu

Shuliang Lee

Joseph A Moore, Iii

Thomas F N Haxell

Michael J Kelly

Michael E Liquori

Joseph A Iii Moore

The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

Inhibitors of Akt activity

The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.

Inhibitors of AKT activity

The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancer 

Substituted [1,2,4]triazolo[4',3&#x2032;:1,6]pyrido[2,3-b]pyrazines of the formula D

Growing community of inventors

Kanagawa, Japan

Yu Onozaki